DE69920497D1 - Liponsaürederivate und deren verwendung bei der behandlung von krankheiten - Google Patents

Liponsaürederivate und deren verwendung bei der behandlung von krankheiten

Info

Publication number
DE69920497D1
DE69920497D1 DE69920497T DE69920497T DE69920497D1 DE 69920497 D1 DE69920497 D1 DE 69920497D1 DE 69920497 T DE69920497 T DE 69920497T DE 69920497 T DE69920497 T DE 69920497T DE 69920497 D1 DE69920497 D1 DE 69920497D1
Authority
DE
Germany
Prior art keywords
acid derivatives
treating diseases
liponic acid
diseased cells
liponic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920497T
Other languages
English (en)
Other versions
DE69920497T2 (de
Inventor
M Bingham
Zuzana Zachar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Application granted granted Critical
Publication of DE69920497D1 publication Critical patent/DE69920497D1/de
Publication of DE69920497T2 publication Critical patent/DE69920497T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE69920497T 1998-10-26 1999-10-26 Liponsaürederivate und deren verwendung bei der behandlung von krankheiten Expired - Lifetime DE69920497T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10562898P 1998-10-26 1998-10-26
US105628P 1998-10-26
PCT/US1999/025140 WO2000024734A1 (en) 1998-10-26 1999-10-26 Lipoic acid derivatives and their use in treatment of disease

Publications (2)

Publication Number Publication Date
DE69920497D1 true DE69920497D1 (de) 2004-10-28
DE69920497T2 DE69920497T2 (de) 2006-02-09

Family

ID=22306916

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69920497T Expired - Lifetime DE69920497T2 (de) 1998-10-26 1999-10-26 Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE69941800T Expired - Lifetime DE69941800D1 (de) 1998-10-26 1999-10-26 Salze von Liponsaürederivaten und deren Verwendung bei der Behandlung von Krankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69941800T Expired - Lifetime DE69941800D1 (de) 1998-10-26 1999-10-26 Salze von Liponsaürederivaten und deren Verwendung bei der Behandlung von Krankheiten

Country Status (12)

Country Link
US (2) US6331559B1 (de)
EP (3) EP1124820B1 (de)
JP (2) JP4728481B2 (de)
AT (2) ATE451362T1 (de)
AU (1) AU774362B2 (de)
BR (1) BR9914789A (de)
CA (1) CA2348998C (de)
DE (2) DE69920497T2 (de)
ES (2) ES2340488T3 (de)
IL (2) IL142824A0 (de)
MX (1) MXPA01004152A (de)
WO (1) WO2000024734A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
ATE276241T1 (de) * 1998-11-25 2004-10-15 Yissum Res Dev Co Antioxidationsmittel
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2162586B1 (es) * 1999-11-25 2002-07-01 Moraleda Manuel Gomez Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
AU2002229576A1 (en) 2000-11-30 2002-06-11 Basf Aktiengesellschaft Method for producing lipoic acid and dihydrolipoic acid
JP4072062B2 (ja) * 2001-03-19 2008-04-02 千寿製薬株式会社 新規α−リポ酸誘導体およびその用途
US6936641B2 (en) * 2002-06-25 2005-08-30 Johnson & Johnson Vision Care, Inc. Macromer forming catalysts
AU2003251955A1 (en) * 2002-07-16 2004-02-02 Sonus Pharmaceuticals, Inc. Platinum compound
EP1547590A4 (de) * 2002-09-13 2008-07-30 Oga Res Inc Melanin-löscher
CN1964630A (zh) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US20040248982A1 (en) * 2003-06-09 2004-12-09 Dyer Gordon Wayne Use of compounds for the inhibition of proteins and UV protection
AU2004248187A1 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
CA2560059A1 (en) * 2004-03-15 2005-09-29 Sonus Pharmaceuticals, Inc. Platinum carboxylate anticancer compounds
US7582418B2 (en) * 2004-11-03 2009-09-01 Albion Laboratories, Inc. Antimicrobial chelates
WO2006116217A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
JP2008543734A (ja) * 2005-05-02 2008-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 脂肪酸代謝および解糖の阻害を提供する化合物の組み合わせ、または二官能性化合物を用いるヒトの炎症性および増殖性疾患を処置するためのシステムおよび方法
US20070225354A1 (en) * 2006-03-21 2007-09-27 Eric Marchewitz Use of dihydrolipoamide for enhancing physical performance
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
JP5412423B2 (ja) * 2007-04-18 2014-02-12 コーナーストーン ファーマシューティカルズ，インコーポレーテッド リポ酸誘導体
US20080262077A1 (en) 2007-04-18 2008-10-23 Shorr Robert G L Pharmaceutical formulations containing lipoic acid derivatives
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2009110859A1 (en) * 2008-03-04 2009-09-11 Robert Shorr Modulation of enzymatic structure, activity, and/or expression level
KR101715631B1 (ko) 2008-04-01 2017-03-13 안티포딘 파마슈티칼스, 인코포레이티드 피부 관리를 위한 조성물 및 방법
MX2010010867A (es) * 2008-04-04 2011-05-25 Robert Shorr Composicion farmaceutica.
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
WO2010019225A1 (en) * 2008-08-15 2010-02-18 Robert Shorr Pharmaceutical composition
CA2744100C (en) 2008-10-21 2020-06-30 The General Hospital Corporation Cell transplantation
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
WO2010062381A1 (en) * 2008-11-28 2010-06-03 Robert Shorr Organelle-specific drug delivery
JP2012510511A (ja) * 2008-12-01 2012-05-10 インヴアスク セラピューテイックス インコーポレイテッド レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用
CN101787013B (zh) * 2009-01-22 2013-04-24 杭州民生药业有限公司 硫辛酰胺系列衍生物、制备方法及所述衍生物的制药用途
WO2010110887A1 (en) * 2009-03-24 2010-09-30 Robert Shorr Fatty acids
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
WO2011046583A1 (en) * 2009-09-11 2011-04-21 Robert Shorr Pharmaceutical exploitation of oxidative stress in transformed cells
FR2959668B1 (fr) * 2010-05-05 2012-07-13 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011146635A1 (en) * 2010-05-21 2011-11-24 North Texas Medical Associates Malignant neoplasm treatment protocol
CN108504539B (zh) 2010-08-06 2021-11-02 通用医院公司以麻省总医院名义经营 用于细胞处理相关应用的系统和设备
AU2013364387B2 (en) * 2012-12-19 2018-07-19 Paul Bingham Pharmaceutical compounds
US9605012B2 (en) * 2013-01-17 2017-03-28 Garnett Mckeen Laboratory, Inc. Palladium-ruthenium-zinc-organo complexes and methods for their use in the treatment of inflammatory diseases
AU2014398233B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
ES2819175T3 (es) 2014-06-19 2021-04-15 Rafael Pharmaceuticals Inc Compuestos farmacéuticos
US10052305B2 (en) 2015-10-07 2018-08-21 Buck Institute For Research On Aging Lipoic acid and derivatives thereof for the treatment of cystinuria
CN117263907B (zh) * 2023-09-23 2026-01-27 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362916C (de) 1921-08-13 1922-11-02 Eduard Duerr Abnehmbares Mikrometer fuer Schublehren
GB758897A (en) * 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2872458A (en) * 1954-12-30 1959-02-03 Merck & Co Inc Addition product of a metal hydrocarbon mercaptide with an alpha-halogamma-butyrolactone
JPS57123107A (en) * 1981-01-26 1982-07-31 Pola Chem Ind Inc Cosmetic
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
DE3626116A1 (de) 1986-08-01 1988-02-11 Karl Thiel Thermostatische regeleinrichtung fuer heizungen bzw. heizaggregate
DE3629116A1 (de) * 1986-08-27 1988-03-10 Asta Pharma Ag Verfahren zur herstellung enantiomerenreiner r-(+)-(alpha)-liponsaeure und s-(-)-(alpha)-liponsaeure (thioctsaeure) sowie nonen- beziehungsweise mesylderivate als zwischenprodukte hierfuer
DE3900649A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
JPH03193758A (ja) * 1989-12-25 1991-08-23 Nisshin Oil Mills Ltd:The 新規γ―アミノ酪酸誘導体
ES2112874T3 (es) * 1991-07-05 1998-04-16 Asta Medica Ag Utilizacion de acidos carboxilicos con contenido en azufre para combatir trastornos de excitacion de origen patofisiologico.
DE4137773A1 (de) * 1991-11-16 1993-05-19 Degussa Herstellung und verwendung von salzen der reinen enantiomere der (alpha)-liponsaeure
WO1994006794A1 (en) 1992-09-24 1994-03-31 National Institutes Of Health Aralkyl diazabicycloalkane derivatives for cns disorders
DE4310142A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE4439477C2 (de) * 1994-11-08 1999-10-21 Asta Medica Ag Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie
DE19601787C1 (de) * 1996-01-19 1997-07-24 Asta Medica Ag Herstellung und Verwendung von Salzen der 6,8-Bis(amidiniumthio)-octansäure
AU737038B2 (en) * 1996-07-05 2001-08-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
EP0855396A1 (de) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Metabolite von Thioctsäure und deren Verwendung
JP4777489B2 (ja) * 1997-03-31 2011-09-21 ザ チルドレンズ メディカル センター コーポレーション アポトーシス性酵素を不活性化するためのニトロシル化
CZ96798A3 (cs) * 1997-04-02 1998-10-14 Sankyo Company Limited Deriváty dithiolanu, jejich příprava a jejich terapeutické účinky
JPH11124379A (ja) * 1997-10-17 1999-05-11 Ss Pharmaceut Co Ltd ジチオリリデンアセトアミド誘導体
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
ES2856125T3 (es) 2016-02-05 2021-09-27 Ea Pharma Co Ltd Derivado de sulfonamida y composición farmacéutica que contiene la misma

Also Published As

Publication number Publication date
WO2000024734A1 (en) 2000-05-04
ES2340488T3 (es) 2010-06-04
AU774362B2 (en) 2004-06-24
MXPA01004152A (es) 2002-06-04
JP2002528446A (ja) 2002-09-03
ATE451362T1 (de) 2009-12-15
JP5727721B2 (ja) 2015-06-03
JP4728481B2 (ja) 2011-07-20
IL142824A0 (en) 2002-03-10
EP2145883A1 (de) 2010-01-20
DE69920497T2 (de) 2006-02-09
AU1324600A (en) 2000-05-15
US20020107234A1 (en) 2002-08-08
EP1124820B1 (de) 2004-09-22
EP1486495B1 (de) 2009-12-09
US6331559B1 (en) 2001-12-18
CA2348998A1 (en) 2000-05-04
DE69941800D1 (de) 2010-01-21
EP1486495A1 (de) 2004-12-15
CA2348998C (en) 2012-03-06
BR9914789A (pt) 2001-10-02
ATE277034T1 (de) 2004-10-15
IL142824A (en) 2010-11-30
JP2010248203A (ja) 2010-11-04
EP1124820A1 (de) 2001-08-22
ES2229790T3 (es) 2005-04-16
US6951887B2 (en) 2005-10-04

Similar Documents

Publication Publication Date Title
DE69920497D1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE3871751D1 (de) Gelbildende organosiloxanzusammensetzungen und deren verwendung.
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
NO962304L (no) BMP-12, BMP-13 og sene-induserende sammensetninger derav
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE69920019D1 (de) Behandlung von mineralfüllstoffen mit phosphaten, diese füllstoffe und deren verwendung
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
DE69004081D1 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
ATE198895T1 (de) Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
DE60013859D1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE59813690D1 (de) Substituierte heterocyclen und deren verwendung in arzneimitteln
ATE208384T1 (de) Verwendung von ascorbyl-gamma-linolenat und von ascorbyl-dihomo-gamma-linolenat zur behandlung von asthma, krebs, kardiovaskulären und inflammatorischen erkrankungen
DE69716896D1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
ATE438361T1 (de) Stent beschichtet mit dna
DE69736858D1 (de) Unsterbliche vogelzellen
ATE254128T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69930725D1 (de) Verfahren und kits zur behandlung von vulvovaginalen candidosen mit mikonazolnitrat
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition